CytRx spiked three hundred twenty-nine percent on cannabinoid receptor trial data in a session that split cannabis equities cleanly down the middle: biotech plays with IP optionality found air while the core MSO cohort sat range-bound, waiting for regulatory clarity that still hasn't arrived.

Read the full US brief for 2026-07-10.